First Light Asset Management, LLC
13F Reported Value
ⓘ$1.1B
Holdings
35
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
First Light Asset Management, LLC disclosed 35 positions worth $1.1B in its Form 13F-HR for Q1 2026, led by $AXGN (Axogen, Inc.) at 11.9% of the equity portfolio, followed by $PVLA and $NEO. During the quarter the fund opened 7 new positions and exited 5 — including a new stake in $TLSI and a full exit from $IRON. The portfolio is most concentrated in Healthcare (84.5% of disclosed assets). All figures are sourced directly from First Light Asset Management, LLC’s Form 13F-HR filing with the SEC under CIK 1600004.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 38.0#2,028
Quality
$132.6M4,002,768 sh - —
Quality
$122.3M980,758 sh - 34.6#2,190
Quality
$72.2M9,729,978 sh - 37.7
Quality
$67.6M5,353,190 sh - —
Quality
$62.0M1,560,991 sh - —
Quality
$48.5M576,684 sh - —
Quality
$44.3M3,190,645 sh - 33.3
Quality
$41.8M878,848 sh - 26.5
Quality
$39.6M1,089,670 sh - 43.3
Quality
$37.2M6,072,563 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Axogen, Inc.$AXGN | 38.0#2,028 | $132.6M | 4,002,768 |
 PALVELLA THERAPEUTICS, INC.$PVLA | — | $122.3M | 980,758 |
 NEOGENOMICS INC$NEO | 34.6#2,190 | $72.2M | 9,729,978 |
 SI-BONE, Inc.$SIBN | 37.7 | $67.6M | 5,353,190 |
 Centessa Pharmaceuticals plc$CNTA | — | $62.0M | 1,560,991 |
 Apogee Therapeutics, Inc.$APGE | — | $48.5M | 576,684 |
 Amylyx Pharmaceuticals, Inc.$AMLX | — | $44.3M | 3,190,645 |
 Twist Bioscience Corp$TWST | 33.3 | $41.8M | 878,848 |
 Crinetics Pharmaceuticals, Inc.$CRNX | 26.5 | $39.6M | 1,089,670 |
 908 Devices Inc.$MASS | 43.3 | $37.2M | 6,072,563 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of First Light Asset Management, LLC's 35 positions.
Showing top 10 of 35 holdings.
Sector Allocation
Healthcare
$942.7M
Technology
$173.2M
Full Holdings — First Light Asset Management, LLC (Q1 2026)
All 35 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $AXGN | Axogen, Inc. | $132.6M | 11.9% | -24% | 38 |
| 2 | $PVLA | PALVELLA THERAPEUTICS, INC. | $122.3M | 11.0% | +38% | — |
| 3 | $NEO | NEOGENOMICS INC | $72.2M | 6.5% | -3% | 34.6 |
| 4 | $SIBN | SI-BONE, Inc. | $67.6M | 6.1% | +6% | 37.7 |
| 5 | $CNTA | Centessa Pharmaceuticals plc | $62.0M | 5.6% | -32% | — |
| 6 | $APGE | Apogee Therapeutics, Inc. | $48.5M | 4.3% | +102% | — |
| 7 | $AMLX | Amylyx Pharmaceuticals, Inc. | $44.3M | 4.0% | -5% | — |
| 8 | $TWST | Twist Bioscience Corp | $41.8M | 3.7% | -23% | 33.3 |
| 9 | $CRNX | Crinetics Pharmaceuticals, Inc. | $39.6M | 3.5% | -9% | 26.5 |
| 10 | $MASS | 908 Devices Inc. | $37.2M | 3.3% | +26% | 43.3 |
| 11 |  $NPCE | NeuroPace Inc | $32.3M | 2.9% | +82% | 30.5 |
| 12 |  $EWTX | Edgewise Therapeutics, Inc. | $31.6M | 2.8% | -36% | — |
| 13 |  $ANAB | ANAPTYSBIO, INC | $31.4M | 2.8% | -13% | 29.4 |
| 14 |  $SLP | Simulations Plus, Inc. | $31.1M | 2.8% | +34% | 37.4 |
| 15 |  $GH | Guardant Health, Inc. | $25.9M | 2.3% | -5% | 36.1 |
| 16 |  $TNDM | TANDEM DIABETES CARE INC | $25.2M | 2.3% | +21% | 34.8 |
| 17 |  $ATRC | AtriCure, Inc. | $20.8M | 1.9% | -38% | 47.6 |
| 18 |  $TLSI | TriSalus Life Sciences, Inc. | $20.3M | 1.8% | NEW | 28.3 |
| 19 |  $TECX | Tectonic Therapeutic, Inc. | $20.0M | 1.8% | NEW | — |
| 20 |  $IRTC | iRhythm Holdings, Inc. | $19.8M | 1.8% | +9% | 41.1 |
| 21 |  $SEPN | Septerna, Inc. | $17.6M | 1.6% | +18% | 44.6 |
| 22 |  $ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $17.5M | 1.6% | -18% | 26.7 |
| 23 |  $HCAT | Health Catalyst, Inc. | $16.4M | 1.5% | -0% | 28.1 |
| 24 |  $OMCL | OMNICELL, INC. | $16.4M | 1.5% | NEW | 45.6 |
| 25 |  $KRMD | KORU Medical Systems, Inc. | $16.3M | 1.5% | -11% | 35.2 |
| 26 |  $WGS | GeneDx Holdings Corp. | $15.6M | 1.4% | NEW | 38.6 |
| 27 |  $WVE | Wave Life Sciences Ltd. | $13.4M | 1.2% | -1% | — |
| 28 |  $VERA | Vera Therapeutics, Inc. | $12.6M | 1.1% | -64% | — |
| 29 |  $MDXG | MIMEDX GROUP, INC. | $11.2M | 1.0% | -6% | 55.6 |
| 30 |  $BFLY | Butterfly Network, Inc. | $10.7M | 1.0% | -5% | 29.5 |
| 31 |  $SGP | SpyGlass Pharma, Inc. | $9.7M | 0.9% | NEW | — |
| 32 |  $ORGO | Organogenesis Holdings Inc. | $8.3M | 0.7% | -9% | 20.5 |
| 33 |  $PCVX | Vaxcyte, Inc. | $8.2M | 0.7% | NEW | — |
| 34 |  $ELVN | Enliven Therapeutics, Inc. | $7.9M | 0.7% | NEW | — |
| 35 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $7.6M | 0.7% | -71% | 30.3 |
New Positions (7)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for First Light Asset Management, LLC including:
Track First Light Asset Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for First Light Asset Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: First Light Asset Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For First Light Asset Management, LLC (SEC CIK: 1600004), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in First Light Asset Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.